BioCentury
ARTICLE | Company News

Baxter's Rixubis gets CHMP nod for hemophilia B

October 25, 2014 12:56 AM UTC

EMA's CHMP recommended marketing authorization of Rixubis ( BAX 326) from Baxter International Inc. (NYSE:BAX) to treat and prevent bleeding in patients with hemophilia B. Approval will include a pharmacovigilance plan. ...